Ventilator-Associated Pneumonia — FRCA Final MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: C — Piperacillin-tazobactam
Piperacillin-tazobactam is the best empirical option. It is an antipseudomonal beta-lactam licensed for VAP and is suitable as monotherapy when the patient is not in septic shock and local susceptibility data support it. The BAL Gram stain also favours Gram-negative coverage. Meropenem would provide appropriate activity but is unnecessarily broad here; carbapenems should generally be reserved for known or strongly suspected resistant organisms, recent relevant antibiotic exposure or failure of narrower treatment. Co-amoxiclav does not reliably cover Pseudomonas and is inadequate for this late VAP scenario. Vancomycin targets Gram-positive organisms, principally when MRSA is suspected, while fluconazole treats susceptible fungal infection rather than bacterial VAP. Therapy must be reviewed promptly against culture and susceptibility results.
Reference: NHS Lothian, Critical Care Antimicrobial Guidance, section 'Bugs and drugs', current webpage accessed August 2026. https://www.rightdecisions.scot.nhs.uk/antimicrobial-prescribing-nhs-lothian/specialty-guidelines/other/critical-care/guidance/